Literature DB >> 33119042

Combination of Osimertinib and Bevacizumab as First-line Treatment for Patients With Metastatic EGFR-Mutant Lung Cancers-Reply.

Adam J Schoenfeld1, Helena A Yu1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33119042     DOI： 10.1001/jamaoncol.2020.4824

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  3 in total

1.  Updated efficacy of adjuvant epirubicin plus cyclophosphamide followed by taxanes versus carboplatin plus taxanes in early triple-negative breast cancer in phase 2 trial: 8.1-year median follow-up.

Authors:  Fangchao Zheng; Feng Du; Wenmiao Wang; Yongsheng Wang; Ming Li; Jiuda Zhao; Xue Wang; Jian Yue; Jiayu Wang; Zixuan Yang; Ruigang Cai; Fei Ma; Ying Fan; Qing Li; Pin Zhang; Binghe Xu; Peng Yuan
Journal:  Breast Cancer Res Treat       Date:  2021-10-14       Impact factor: 4.872

2.  Taking a step down on the reconstruction ladder for head and neck reconstruction during the COVID-19 pandemic.

Authors:  Haroon Ur Rashid; Mamoon Rashid; Nasir Khan; Shayan Shahid Ansari; Noshi Bibi
Journal:  BMC Surg       Date:  2021-03-08       Impact factor: 2.102

Review 3.  Risk for COVID-19 infection in patients with tobacco smoke-associated cancers of the upper and lower airway.

Authors:  Oreste Gallo
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-11-20       Impact factor: 2.503
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.